2025年3月26日 · Exelixis is an oncology-focused biotech company innovating cancer treatments for life. Find out how we're dedicated to giving more patients hope for the future.

If you are a healthcare professional and have a question about an Exelixis product, please contact Exelixis Medical Information at [email protected] or call 1-855-292-3935 (EXEL).

Qualified and interested candidates should apply to current openings on our Exelixis Careers website or on LinkedIn, Glassdoor and Indeed. Exelixis accepts no responsibility for any costs or charges incurred as a result of fraudulent activity.

* Sairopa B.V. (Sairopa) and Exelixis have an exclusive clinical development and option agreement providing Exelixis the right to acquire ADU-1805

2025年2月15日 · Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Exelixis extends its impact through strategic collaborations across drug discovery, development and commercialization, building on our long history of productive partnerships to move our molecules and business forward.

2025年1月25日 · With zanzalintinib, Exelixis sought to build upon its extensive experience with the target profile of cabozantinib, the company’s flagship medicine, while improving key …

I am energized by scientific learnings that lead to understanding, and I’m excited to work with my team to bring the next generation of Exelixis medicines to patients.

As we seek to improve the treatment of patients with cancer, Exelixis is addressing a broad array of targets selected based on rigorous scientific and clinical evidence with the goal of developing a diverse pipeline with clinically meaningful potential.

One of Exelixis’ greatest strengths is its culture of focused execution. We’re committed to moving quickly while turning over every stone to bring new standards of care to physicians and …